Telix HY26 Results Announcement
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The report indicates double-digit revenue growth and improvements in gross margin, driven by successful product strategies and collaborations. The company also reported significant advancements in its therapeutic programs and a strategic collaboration with Regeneron. Additionally, Telix has established an at-the-market facility to enhance access to its securities on the Nasdaq stock exchange.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Telix HY26 Appendix 4D and Interim Report
- Telix to Host R&D Day in New York City on September 22, 2026
- Telix H1 2026 Results: Investor Webcast Notification
- TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
- Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Later from Telix Pharmaceuticals
- Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
- Telix Appoints David Gill as Chair
- Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
- Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
- FDA Approves Telix Brain Cancer Imaging Drug Pixclara
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals